Third, multiple lines of evidence from basic research indicate that the use of SGLT2 inhibitors contributes to metabolic reprogramming and the regulation of hypoxia, inflammation, and oxidative stress in conditions such as sepsis, heart failure, and nephrotoxin- or contrast media-induced acute kidney injury [81,82]. Here, SLC5A2 is linked to heart failure.